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Pretreatment of newborn human foreskin epidermal cells 
(Ee) with L-leucyl-L-leucine methyl ester (Leu-Leu-OME) 
was found to dramatically inhibit their ability to serve as 
alloantigen-presenting cells in a primary, one-way, allogen-
eic mixed epidermal cell-lymphocyte reaction (MECLR) 
without significantly affecting EC viability. The Leu-Leu-
OME-induced MECLR inhibition could not be accounted 
for by a cytotoxic effect on epidermal Langerhans cells (Le), 
the class II major histocompatibility (MHe) antigen-bearing 
EC type that is fully responsible for alloantigen presentation 
in a primary allogeneic MECLR. Pretreatment with Leu-
Leu-OME was found to inhibit the culture-induced increase 
in surface expression of HLA-DR molecules on LC. These 
T he dipeptide L-Ieucyl-L-Ieucine O-methyl ester (Leu-Leu-OME) has been shown to selectively inactivate certain immunocompetent cells of myeloid origin [1,2]. Based on these properties, a potential therapeu-tic use of Leu-Leu-OME has been proposed, i.e., to 
deplete alloreactive donor cells prior to allogeneic bone marrow 
transplantation [2 - 4]. In contrast to expanding knowledge on Leu-
Leu-OME effects on blood leukocytes, little is known about its 
impact on immunocompetent cells within epidermis. This 
prompted us to examine the effects of Leu-Leu-OME on epidermal 
Langerhans cells (Le). In this short paper we provide some general 
information on the mode of action and use of Leu-Leu-OME, and 
Reprint requests to: Dr. Rick D. Sontheimer, Department of Dermatol-
ogy, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, 
Dallas, TX 75235 . 
Abbreviations: 
CTL: cytotoxic T lymphocyte 
DPPI: dipeptidyl-dipeptidase I 
EC: epidermal cells 
GVHD: graft versus host disease 
ICAM-l: intracellular adhesion molecule 1 
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Leu-Leu-OME: L-leucyl-L-leucine O-methyl ester 
LFA-l,3: late functional antigen 1,3 
MECLR: mixed epidermal cell leukocyte reaction 
MHC: major histocompatibility complex 
NK: natural killer 
PBMC: peripheral blood mononuclear cells 
findings suggest that in addition to its cytotoxic effect on 
cells containing high levels of dipeptidyl peptidase I, Leu-
Leu-OME can also perturb alloantigen-presenting cells that 
are not killed by this agent by modulating HLA-D region 
antigen expression, perhaps through its capacity to neutralize 
acid compartments within cells. In addition, these studies 
support the notion that the culture-induced upregulation of 
class II MHC antigens on epidermal LC is functionally asso-
ciated with the enhanced alloantigen-presenting capabilities 
that these cells display after short-term culture and suggest 
that newly synthesized class II antigens might be critical to 
the alloantigen-presenting cell capabilities of LC. ] Itwest 
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review our recent studies on the distinct immunomodulatory effects 
of this agent on LC. 
MODE OF ACTION OF Leu-Leu-OME 
Leu-Leu-OME is the biologically active condensation product of 
L-Ieucine-O-methyl ester that is generated in vivo by monocytes or 
polymorphonuclear leukocytes; in addition, Leu-Leu-OME can 
als~ be synthesized in vitro [2) . Leu-Leu-OME is selectively cyto-
tOXIC for monocytes, natural kIller (NK) cells and cytotoxic T lym-
phocyte (CTL) cells, although sparing eosinophils, B cells, T-
hel per cells, dendritic cells, fibroblasts, endothelial cells, and a 
variety of myeloid an.d non-myeloid cell.lines [1,2,5] . In susceptible 
cells Leu-Leu-OME lllduces rapid swelllllg and subsequent disrup-
tion of lysosomes followed by autolysis and cell death [2,5]. 
This toxicity depends upon a sequence of events initiated by the 
specific ~ptake of Leu-Leu-OME into cells via a novel transporter 
mechamsm [6]. Thereafter, Leu-Leu-OME accumulates within Iy-
sosomes and endosomes, where it leads to a rise in pH [6,7]. Within 
lysosomes Leu-Leu-OME is converted into membranolytic poly-
meriza~ion products. of the g~neral structure {Leu-Leu}n-OME by 
the aCtlon of dlpeptldyl-peptl~ase I {DPPI}, a I~sosomal thiol pro-
tease formerly named cathepslll C [6,7] . The lytic potential of such 
polymers is most likely based on their detergent properties, and 
extends beyond I ysosomes to other cytoplasmic organelles and possi-
bly to the cell membrane [6,7]. Leu-Leu-OME-mediated cell death 
is also associated with early nuclear damage and DNA fragmenta-
tion [8]. Importantly, killing of susceptible cells is prevented by 
zinc, a known endonuclease inhibitor, suggesting that DPPI-gener-
ated {Leu-Leu}n-OME polymers trigger endonuclease-mediated 
DNA fragmentation that is ultimately responsible for cell death [8]. 
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Table I. Leu-Leu-OME Abrogates the Capacity of Human LC 
to Stimulate Allogeneic PBMC" 
Stimulator EC 
(per well) 
12,500 
12,500 
25,000 
25,000 
50,000 
50,000 
Leu-Leu-OME 
+ 
+ 
+ 
Proliferation of Responder PBMC 
Delta cpm ± SEM 
11,450 ± 1,340 
125 ± 15 
16,600 ± 2,650 
325 ± 450 
15,450 ± 2,250 
1,760 ± 540 
• y-irradiated EC, enriched for LC, were treated with Leu-Lcu-OME (15 min, room 
temperature, 250 pM), by a protocol that has been shown to remove effectively all 
monocytes, NK cells, and CTL from human peripheral blood [1]. EC were then 
incubated for 18 hat 37"C in5% CO2 , washed, and subsequently addedatthe indicated 
concentrations to 5 X 10' allogeneic responder PBMC in microtiter wells. After 6 d of 
co-culture, each well was pulsed with 1 pCi of tritiated thymidine (['H]-TdR). After an 
additional 18 h, PBMC proliferation was determined by ['H]-TdR} incorporation. 
Data are expressed as delta cpm (cpm ofEC co-cultured with PBMC minus cpm ofEC 
and PBMC cultured alone) ± standard error of the mean (SEM) of triplicate measure-
ments. Background proliferation of EC or PBMC cultured alone did not exceed 
1000 cpm. 
The selective nature of Leu-Leu-OME-mediated toxicity may 
therefore be related to a) the rate of uptake via the specific trans-
porter (increased in susceptible cells); b) the conversion of the agent 
to (Leu-Leu)n-OME polymers by DPPI (DPPI is highly enriched in 
susceptible cells); and c) endonuclease-mediated DNA fragmenta-
tion. 
USE OF Leu-Leu-OME 
Based on its selective cytotoxicity Leu-Leu-OME has been used in 
vitro to remove susceptible cells from mixed cell populations, for 
example, to deplete monocytes, NK cells, and CTL from peripheral 
blood [1]. The utility ofLeu-Leu-OME- mediated depletion of allo-
reactive CTL has also been demonstrated in vivo: For example, 
Leu-Leu-OME treatment of donor bone marrow or spleen cells 
protected recipient mice from the development of lethal graft versus 
host disease (GVHD) [2-4]. Furthermore, Leu-Leu-OME treat-
ment of recipient-type CTL has been shown to ameliorate the 
course of allograft rejection [2] . Although many of these observa-
tions were made in selected animal models, they suggest that Leu-
Leu-OME may prove to be a useful therapeutic agent in the preven-
tion of GVHD or allograft rejection in humans. 
IMMUNOMODULATORY EFFECTS OF Leu-Leu-OME 
ON LANGERHANS CELLS 
Our initial interest in Leu-Leu-OME was purely technical. Because 
this agent removes selected leukocytes from heterogeneous cell pop-
ulations [1], we questioned whether it could be used to deplete LC 
from mixed epidermal cell preparations (EC). To address this issue, 
we examined the effects of Leu-Leu-OME on the capacity ofLC to 
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stimulate proliferation of allogeneic peripheral blood mononucleaT 
cells (PBMC), using a primary, one-way mixed epidermal cell leu-
kocyte reaction (MECLR). Pretreatment of EC with Leu-Leu-
OME completely abrogated the capacity of human LC to function 
as accessory cells in the MECLR (Table I). Similar results were 
obtained when highly purified CD4+ T cells were used as respon-
ders (data not shown). 
To elucidate whether this loss of accessory cell function was due 
to toxicity of Leu-Leu-OME for LC, we determined the viability of 
epidermal cells 18 h or 66 h after Leu-Leu-OME treatment by mul-
tiparameter flow cytometry (Table II). There were no differences in 
LC viability when the untreated and the Leu-Leu-OME-treated 
group were compared (Table II). Furthermore, Leu-Leu-OME did 
not exert significant toxicity for keratinocytes (KC) (Table II). Im-
portantly, the Leu-Leu-OME used in our experiments was biologi-
cally active, because it depleted all monocytes from PBMC prepara-
tions (Table II) . We conclude that, in our system, Leu-Leu-OME is 
not toxic for LC. There are several explanations for this finding. 
L~, like other non-susceptible cells, may be less efficient in incorpo-
ratll1g Leu-Leu-OME via the specific transporter [6] . Alternatively, 
LC may have a reduced quantity and/or activity of DPPI, as re-
ported for other resistant cell types [7] . Yet another possibility is 
that LC are less capable of endonuclease-mediated DNA fragmenta-
tion [8]. 
How, if not by direct cytotoxicity, does Leu-Leu-OME distort 
the ~mmune function ofLC? Because the allostimulatory capacity of 
LC IS thought to depend upon the expression and/or upregulation 
of MHC class II molecules [9 - 11], we questioned whether Leu-
Leu-OME modulates MHC class II expression by LC. Indeed, Leu-
Le~-OME c~mpletely prevented the capacity of LC to upregulate 
their expreSSIOn of HLA-DR Ag during tissue culture (Table III) . 
Does this imply that Leu-Leu-OME distorts the allostimulatory 
potential ofLC by interfering with their ability to upregulate MHC 
class II Ag? To address this question, we compared fresh and cul-
tur~d LC (wl~i~l~ had already upregulated their class II molecules) in 
thelT susceptibilIty to Leu-Leu-OME. Again, Leu-Leu-OME dis-
torted the capacity of fresh LC to induce proliferation of alloreactive 
PBMC (Table IV). By contrast, LC cultured for 66 h prior to Leu-
Leu-OME treatment were completely resistant to this suppressive 
effect of Leu-Leu-OME (Table IV). 
Taken together, our results support the hyrothesis that Leu-Leu-
OME di~torts the ~llostimulatory capacity 0 human LC through a 
modulatIOn of thelf MHC class II Ag expression. These findings do 
not exclude that Leu-Leu-OME also affects expression of other 
mo~ecu~es on LC known to contribute to their allostimulatory ca-
paCity, I.e., I.C~-1, LFA-l , or LFA-3 ([9]; T eunissen et al in this 
Issu.e). At thiS POll1t, we can only speculate on the mechanisms by 
wluch Leu-Leu-OME modulates MHC class II expression by LC. 
Our current working hypothesis is based on the knowledge that 
Leu-Leu-OME accumulates in lysosomes and endosomes where it 
ll1creases the pH [1,7]. This increase in pH may interfere with the 
transport of class II molecules to the cell surface, for example, by 
Table II. Effects of Leu-Leu-OME on Epidermal Cell and Monocyte Viability" 
18 h 66 h 
Leu-Leu-OME Controls Leu-Leu-OME Controls 
Live HLA-DR+/CD1a+ EC (LC) 11 % 10% 5% 4% 
Dead HLA-DR+jCD1a+ EC (LC) 1% 1% 5% 6% 
Live HLA-DR- /CD1a- EC (KC) 68% 73% 45% 48% 
Dead HLA-DR- /CDla- EC (KC) 20% 16% 45% 42% 
Live CD14+ PBMC (monocytes) 0% 15% NOb NO 
Dead CDI4+ PBMC (monocytes) 15% 0% NO NO' 
• EC, enriched for LC, or PBMC were treated with Lcu-Lcu-OME as described in Table l. After 18 or 66 h of culture (37"C, 5% CO2 ) LC were identified among epidermal cells 
by their expression ofHLA-DR or CD 1a Ag, the remaining HLA-DR- /CD Ia- EC were defined operationally as KC. Monocytes were identified by their express ion of the CD14 
Ag. Cells were then stained with the vital dye propidium iodide and viability of different cellular subsets was determined by two-color fl ow cytometry using a Becton-Dickinson 
FACscan, equipped with a Consort 30 program. Data arc expressed as percent of total EC or PBMC, respectively. 
• ND, not done. 
, Because all monocytes were ki lled at 18 h following Lcu-Lcu-OME treatment, no viability tests were performed at 66 h. 
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Table III. Leu-Leu-OME Modulates MHC Class II 
Molecule Expression in LCn 
Fresh EC 
Fresh EC 
Cultured EC 
Cultured EC 
Leu-Leu-OME 
+ 
+ 
Mean Fluorescence Intensity 
of HLA-DR+ EC 
210 
192 
950 
176 
• EC were tre.ted with Leu-Leu-OME as described in Table I. After 18 or 66 h of 
culture (37 °C, 5% CO2) EC were stained with fluorescein. ted .nti-HLA-DR MoAb 
and analyzed fl ow cytometrically as described in Table II . The fluorescent staining is 
presented quantitatively as the mean fluorescence intensity (reflecting mean fluores-
cence ofHLA-DR+ EC on a log scale). 
Table IV. Cultured LC Are Resistant to the 
Immunosuppressive Effects of Leu-Leu-OMEn 
Stimulator EC 
Fresh EC 
Frcsh EC 
Cultured EC 
Cultured EC 
Leu-Leu-OME 
+ 
+ 
Proliferation of Respondcr PBMC 
Delta cpm ± SEM 
12,450 ± 2,640 
5,625 ± 15 
11,450 ± 1,150 
11,280 ± 1,450 
• EC were Leu-Leu-OME treated immediately after isolation (fresh EC) or following 
tissue culture (48 h, 37"C, 5% CO2) (cultured EC) , washed extensively, incubatcd for 
another 18 h, and thcn used as stimulators in a primary one-way MECLR as described in 
Table I. 
inhibiting the release of the invariant chain [12,13]. This notion is 
supported by our preliminary findings that another lysosomotropic 
agent, ammonium chloride, also inhibits the allostimulatory capac-
ity of human LC, presumably through modulation of their HLA-
DR expression. 
CONCLUDING REMARKS 
We have shown Leu-Leu-OME perturbs thc capacity of human LC 
to activate alloreactive T cells. This immunosuppressive effect is not 
due to direct toxicity of this agent for LC or for keratinocytes (KC) ; 
instead it is associated with a modulation ofHLA-DR Ag expression 
on LC. It is not unreasonable to speculate that Leu-Leu-OME may 
perturb other immune functions ofLC, i.e., their capacity to present 
protein Ag or haptens to reactive T ceHs. In this context, one may 
envision a role for this agent in the treatment of inflammatory skin 
diseases known to be induced by Langerhans ceHs. 
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